Rajan Sharma
Stock Analyst at Goldman Sachs
(3.04)
# 2,595
Out of 4,574 analysts
195
Total ratings
55%
Success rate
3%
Average return
Main Sectors:
Stocks Rated by Rajan Sharma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0QW0 argenx SE | Maintained: Buy | €885.00 → €907.00 | €815.30 | +11.25% | 17 | Jul 24, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 2,300 → kr 2,350 | kr 1,877 | +25.17% | 6 | Jul 21, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,370p | 12,670p | +29.20% | 40 | Jul 9, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 1,870p → 1,890p | 1,920p | -1.54% | 30 | Jun 30, 2026 | |
| IMTX Immatics | Rated: Buy | $11 → $12 | $9.08 | +34.36% | 4 | May 12, 2026 | |
| IMCR Immunocore Holdings | Maintained: Buy | $72 → $73 | $35.00 | +108.57% | 12 | May 7, 2026 | |
| GMAB Genmab | Upgraded: Buy | $26 → $31 | $28.87 | +5.65% | 4 | Apr 22, 2026 | |
| VALN Valneva SE | Downgraded: Sell | $7.5 → $4.9 | $4.78 | +2.51% | 5 | Apr 22, 2026 | |
| DBVT DBV Technologies | Maintained: Sell | $7.25 → $5.81 | $13.63 | -57.37% | 3 | Apr 9, 2026 | |
| EPA: DBV DBV Technologies S.A. | Rated: Sell | €1.30 → €1.01 | €2.38 | -57.56% | 5 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | €25.00 → €18.00 | €23.15 | -22.25% | 8 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €304.00 → €299.00 | €240.88 | +24.13% | 7 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $813 → $910 | $918.22 | -0.90% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.91 | - | 1 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.59 | - | 5 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7.6 → $5.7 | $1.45 | +293.10% | 5 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $45 | $62.84 | -28.39% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €2.85 → €3.30 | €2.11 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $81.93 | n/a | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $154 → $168 | $45.01 | n/a | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 2.00 | CHF 6.17 | n/a | 8 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $47 | $51.35 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $126.90 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $35.01 | n/a | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €90.00 → €100.00 | €158.40 | n/a | 6 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €44.00 | €51.35 | n/a | 7 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $20 | $11.01 | n/a | 2 | May 4, 2022 |
argenx SE
Jul 24, 2026
Maintained: Buy
Price Target: €885.00 → €907.00
Current: €815.30
Upside: +11.25%
Genmab A/S
Jul 21, 2026
Maintained: Buy
Price Target: kr 2,300 → kr 2,350
Current: kr 1,877
Upside: +25.17%
AstraZeneca PLC
Jul 9, 2026
Maintained: Buy
Price Target: 16,370p
Current: 12,670p
Upside: +29.20%
GSK plc
Jun 30, 2026
Maintained: Hold
Price Target: 1,870p → 1,890p
Current: 1,920p
Upside: -1.54%
Immatics
May 12, 2026
Rated: Buy
Price Target: $11 → $12
Current: $9.08
Upside: +34.36%
Immunocore Holdings
May 7, 2026
Maintained: Buy
Price Target: $72 → $73
Current: $35.00
Upside: +108.57%
Genmab
Apr 22, 2026
Upgraded: Buy
Price Target: $26 → $31
Current: $28.87
Upside: +5.65%
Valneva SE
Apr 22, 2026
Downgraded: Sell
Price Target: $7.5 → $4.9
Current: $4.78
Upside: +2.51%
DBV Technologies
Apr 9, 2026
Maintained: Sell
Price Target: $7.25 → $5.81
Current: $13.63
Upside: -57.37%
DBV Technologies S.A.
Apr 9, 2026
Rated: Sell
Price Target: €1.30 → €1.01
Current: €2.38
Upside: -57.56%
Apr 9, 2026
Rated: Hold
Price Target: €25.00 → €18.00
Current: €23.15
Upside: -22.25%
Mar 2, 2026
Maintained: Buy
Price Target: €304.00 → €299.00
Current: €240.88
Upside: +24.13%
Feb 26, 2026
Maintained: Buy
Price Target: $813 → $910
Current: $918.22
Upside: -0.90%
Feb 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.91
Upside: -
Jan 9, 2026
Rated: Hold
Price Target: n/a
Current: $1.59
Upside: -
Nov 13, 2025
Maintained: Buy
Price Target: $7.6 → $5.7
Current: $1.45
Upside: +293.10%
Jul 30, 2025
Maintained: Buy
Price Target: $35 → $45
Current: $62.84
Upside: -28.39%
Mar 21, 2025
Maintained: Hold
Price Target: €2.85 → €3.30
Current: €2.11
Upside: n/a
Oct 3, 2024
Maintained: Hold
Price Target: n/a
Current: $81.93
Upside: n/a
Aug 16, 2024
Maintained: Buy
Price Target: $154 → $168
Current: $45.01
Upside: n/a
Jul 30, 2024
Maintained: Hold
Price Target: CHF 2.00
Current: CHF 6.17
Upside: n/a
May 30, 2024
Initiated Coverage: Hold
Price Target: $47
Current: $51.35
Upside: n/a
May 30, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $126.90
Upside: n/a
Dec 20, 2023
Maintained: Buy
Price Target: n/a
Current: $35.01
Upside: n/a
Feb 13, 2023
Maintained: Hold
Price Target: €90.00 → €100.00
Current: €158.40
Upside: n/a
May 16, 2022
Maintained: Hold
Price Target: €44.00
Current: €51.35
Upside: n/a
May 4, 2022
Downgraded: Hold
Price Target: $40 → $20
Current: $11.01
Upside: n/a